Allogene Therapeutics, Inc. (ALLO) Operating income 2018–2025
Allogene Therapeutics, Inc. (ALLO) annual operating income history from SEC filings — each fiscal year as reported.
-$209.3MFY2025 · since FY2018: -$192.8M → -$209.3M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$209.3M | +23.4% |
| FY2024 | -$273.2M | +16.6% |
| FY2023 | -$327.7M | +2.3% |
| FY2022 | -$335.5M | -86.2% |
| FY2021 | -$180.2M | +30.2% |
| FY2020 | -$258.2M | -27.8% |
| FY2019 | -$202.0M | -4.8% |
| FY2018 | -$192.8M | — |
Source: SEC XBRL filings · For reference only · Not investment advice